NEUROCRINE BIOSCIENCES INC Cash and Cash Equivalents, Period Increase (Decrease)
NEUROCRINE BIOSCIENCES INC (NBIX) reported Cash and Cash Equivalents, Period Increase (Decrease) of $171.44 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-13.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-02-13
- NEUROCRINE BIOSCIENCES INC cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was -$13.11M.
- NEUROCRINE BIOSCIENCES INC cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$41.68M, a 408.40% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was $245.41M.
- NEUROCRINE BIOSCIENCES INC cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$19.18M, a 146.66% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC cash and cash equivalents, period increase (decrease) for fiscal 2017 was $171.44M, a 1789.83% increase from fiscal 2016.
- NEUROCRINE BIOSCIENCES INC cash and cash equivalents, period increase (decrease) for fiscal 2016 was $9.07M, a 78.99% decline from fiscal 2015.
- NEUROCRINE BIOSCIENCES INC cash and cash equivalents, period increase (decrease) for fiscal 2015 was $43.18M.
- NEUROCRINE BIOSCIENCES INC cash and cash equivalents, period increase (decrease) for fiscal 2014 was -$13.78M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$13.11M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | -$54.79M derived: sum of 2 quarters · filed 2018-02-13 | $190.63M derived: sum of 3 quarters · filed 2018-02-13 | $171.44M 10-K · filed 2018-02-13 |
| 2017-09-30 | -$41.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $203.73M derived: sum of 2 quarters · filed 2017-11-01 | $184.55M 10-Q · filed 2017-11-01 | $168.06M derived: sum of 4 quarters · filed 2018-02-13 |
| 2017-06-30 | $245.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $226.23M 10-Q · filed 2017-08-03 | $209.74M derived: sum of 3 quarters · filed 2018-02-13 | $223.25M derived: sum of 4 quarters · filed 2018-02-13 |
| 2017-03-31 | -$19.18M 10-Q · filed 2017-05-09 | -$35.67M derived: sum of 2 quarters · filed 2018-02-13 | -$22.16M derived: sum of 3 quarters · filed 2018-02-13 | -$51.21M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-12-31 | -$16.49M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | -$2.98M derived: sum of 2 quarters · filed 2018-02-13 | -$32.03M derived: sum of 3 quarters · filed 2018-02-13 | $9.07M 10-K · filed 2018-02-13 |
| 2016-09-30 | $13.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | -$15.54M derived: sum of 2 quarters · filed 2017-11-01 | $25.57M 10-Q · filed 2017-11-01 | $33.38M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-30 | -$29.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $12.05M 10-Q · filed 2017-08-03 | $19.87M derived: sum of 3 quarters · filed 2018-02-13 | -$45.82M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-03-31 | $41.11M 10-Q · filed 2017-05-09 | $48.92M derived: sum of 2 quarters · filed 2018-02-13 | -$16.77M derived: sum of 3 quarters · filed 2018-02-13 | -$54.96M derived: sum of 4 quarters · filed 2018-02-13 |
| 2015-12-31 | $7.82M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | -$57.88M derived: sum of 2 quarters · filed 2018-02-13 | -$96.07M derived: sum of 3 quarters · filed 2018-02-13 | $43.18M 10-K · filed 2018-02-13 |
| 2015-09-30 | -$65.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | -$103.88M derived: sum of 2 quarters · filed 2016-11-02 | $35.36M 10-Q · filed 2016-11-02 | $37.33M derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-06-30 | -$38.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $101.06M 10-Q · filed 2016-08-03 | $103.02M derived: sum of 3 quarters · filed 2017-02-14 | $94.63M derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-03-31 | $139.25M 10-Q · filed 2016-05-05 | $141.22M derived: sum of 2 quarters · filed 2017-02-14 | $132.82M derived: sum of 3 quarters · filed 2017-02-14 | $64.73M derived: sum of 4 quarters · filed 2017-02-14 |
| 2014-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | -$6.43M derived: sum of 2 quarters · filed 2017-02-14 | -$74.52M derived: sum of 3 quarters · filed 2017-02-14 | -$13.78M 10-K · filed 2017-02-14 |
| 2014-09-30 | -$8.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-29 | -$76.49M derived: sum of 2 quarters · filed 2015-10-29 | -$15.74M 10-Q · filed 2015-10-29 | -$5.84M derived: sum of 4 quarters · filed 2016-02-11 |
| 2014-06-30 | -$68.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-29 | -$7.34M 10-Q · filed 2015-07-29 | $2.56M derived: sum of 3 quarters · filed 2016-02-11 | -$6.87M derived: sum of 4 quarters · filed 2016-02-11 |
| 2014-03-31 | $60.74M 10-Q · filed 2015-04-30 | $70.64M derived: sum of 2 quarters · filed 2016-02-11 | $61.22M derived: sum of 3 quarters · filed 2016-02-11 | $73.98M derived: sum of 4 quarters · filed 2016-02-11 |
| 2013-12-31 | $9.90M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $476.00K derived: sum of 2 quarters · filed 2016-02-11 | $13.23M derived: sum of 3 quarters · filed 2016-02-11 | -$18.96M 10-K · filed 2016-02-11 |
| 2013-09-30 | -$9.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $3.33M derived: sum of 2 quarters · filed 2014-11-04 | -$28.86M 10-Q · filed 2014-11-04 | -$9.60M derived: sum of 4 quarters · filed 2015-02-09 |
| 2013-06-30 | $12.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-06 | -$19.44M 10-Q · filed 2014-08-06 | -$175.00K derived: sum of 3 quarters · filed 2015-02-09 | $2.29M derived: sum of 4 quarters · filed 2015-02-09 |
| 2013-03-31 | -$32.20M 10-Q · filed 2014-05-01 | -$12.93M derived: sum of 2 quarters · filed 2015-02-09 | -$10.46M derived: sum of 3 quarters · filed 2015-02-09 | -$45.38M derived: sum of 4 quarters · filed 2015-02-09 |
| 2012-12-31 | $19.27M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-09 | $21.74M derived: sum of 2 quarters · filed 2015-02-09 | -$13.19M derived: sum of 3 quarters · filed 2015-02-09 | $13.65M 10-K · filed 2015-02-09 |
| 2012-09-30 | $2.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-29 | -$32.45M derived: sum of 2 quarters · filed 2013-10-29 | -$5.62M 10-Q · filed 2013-10-29 | $4.97M derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-06-30 | -$34.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-26 | -$8.09M 10-Q · filed 2013-07-26 | $2.50M derived: sum of 3 quarters · filed 2014-02-11 | $23.18M derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-03-31 | $26.83M 10-Q · filed 2013-05-02 | $37.42M derived: sum of 2 quarters · filed 2014-02-11 | $58.10M derived: sum of 3 quarters · filed 2014-02-11 | $52.55M derived: sum of 4 quarters · filed 2014-02-11 |
| 2011-12-31 | $10.59M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | $31.27M derived: sum of 2 quarters · filed 2014-02-11 | $25.71M derived: sum of 3 quarters · filed 2014-02-11 | -$3.94M 10-K · filed 2014-02-11 |
| 2011-09-30 | $20.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-31 | $15.12M derived: sum of 2 quarters · filed 2012-10-31 | -$14.54M 10-Q · filed 2012-10-31 | -$37.81M derived: sum of 4 quarters · filed 2013-02-08 |
| 2011-06-30 | -$5.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-31 | -$35.21M 10-Q · filed 2012-07-31 | -$58.49M derived: sum of 3 quarters · filed 2013-02-08 | -$76.28M derived: sum of 4 quarters · filed 2013-02-08 |
| 2011-03-31 | -$29.66M 10-Q · filed 2012-05-02 | -$52.94M derived: sum of 2 quarters · filed 2013-02-08 | -$70.73M derived: sum of 3 quarters · filed 2013-02-08 | |
| 2010-12-31 | -$23.28M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-08 | -$41.07M derived: sum of 2 quarters · filed 2013-02-08 | $16.72M 10-K · filed 2013-02-08 | |
| 2010-09-30 | -$17.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-31 | $40.00M 10-Q · filed 2011-10-31 | ||
| 2010-06-30 | $57.79M 10-Q · filed 2011-07-29 | |||
| 2009-12-31 | -$31.14M 10-K · filed 2012-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |